Drug intelligence / Profile preview

L60c

Development stage: Unknown
Lead developer: Beijing Chineo Medical Technology
Modality: Cell Therapies
Administration: Intravenous

Overview

L60c is an investigational immune cell therapy developed by CHINEO MED (BEIJING) CO., LTD. It is administered as an injection and is currently undergoing clinical evaluation for its safety, pharmacokinetics, and efficacy in the treatment of advanced gastric cancer. The developer specializes in advanced cell therapy technologies, including CAR-T, TCR-T, and TIL therapies, for various cancers.

Targets

CD19 (B lymphocyte antigen CD19)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)

Beyond the preview

Go deeper on L60c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L60c.

Explore the full profile